Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Johnson & Johnson's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $650.6B |
|---|
| Revenue (ttm) | 99.3B |
|---|
| Net income (ttm) | 16.1B |
|---|
| EPS (ttm) | $6.58 |
|---|
| Shares out | 2.4B |
|---|
| P/E (trailing) | 41.2x |
|---|
| P/E (forward) | 21.1x |
|---|
| Dividend | $5.36 (1.98%) |
|---|
| Volume | 4,879,063 |
|---|
| Beta | 0.21 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B | +4.6% |
| Gross profit | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B | +3.7% |
| Operating income | $19.36B | $19.64B | $21.85B | $17.44B | $33.55B | +14.7% |
| Net income | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B | +6.4% |
| EPS (diluted) | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 | +9.0% |
| EBITDA | $26.75B | $26.61B | $29.34B | $24.78B | $41.06B | +11.3% |
| R&D | $0 | $0 | $483.0M | $1.84B | $109.0M | — |
| SG&A | $20.12B | $20.25B | $21.51B | $22.87B | $23.68B | +4.2% |
Recent company headlines from major financial publishers.
The Base case reflects our modal underwriting expectation, where disciplined commercial execution in Innovative Medicine balances anticipated loss-of-exclusivity patent expirations. Steady procedure growth across MedTech hospital ecosystems and stable geographic demand across Europe and Asia support steady cash flow compounding. Intrinsic value reaches Fair value $345.55, representing an upside of 28.0% from $269.99 (as of 2026-09-18) with an expected return of 28.0% at a assigned probability of 60.0%.
The Bull case envisions accelerated biopharmaceutical commercial adoption and expanding MedTech procedure volumes. In this outcome, newly launched therapeutics capture leading market share across immunology and oncology indications, while surgical robotics platforms achieve timely regulatory clearances and hospital integration. Consolidated revenue growth outpaces baseline expectations and operating margins expand, driving the valuation target to Potential value $530.18 with an implied return of 96.4% at an estimated likelihood of 20.0%.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.3% | $468 | $524 | $624 | $904 | $778 |
| 6.3% | $372 | $397 | $430 | $481 | $571 |
| 7.3% | $316 | $329 | $346 | $367 | $397 |
| 8.3% | $278 | $286 | $296 | $307 | $322 |
| 9.3% | $251 | $256 | $262 | $269 | $277 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
